<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545142</url>
  </required_header>
  <id_info>
    <org_study_id>031-KOB-0701</org_study_id>
    <nct_id>NCT00545142</nct_id>
  </id_info>
  <brief_title>Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness</brief_title>
  <acronym>SMART-A</acronym>
  <official_title>Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with&#xD;
      Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with&#xD;
      bipolar disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by Korea OIAA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the YMRS total score from baseline to the end of 6-week study</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in YMRS total scores from baseline to the end of 6-week study</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify(Aripiprazole)</intervention_name>
    <description>co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote(Divalproate)</intervention_name>
    <description>co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Mania or mixed episode of Bipolar disorder Bipolar disorder, mania or mixed episode&#xD;
             according to DSM-IV&#xD;
&#xD;
          2. The periods of mania or mixed episode should be within 3 months, and YMRS score at&#xD;
             enrollment be more than 20.&#xD;
&#xD;
          3. Male and female between the age of 18 and 65 (In case of child-bearing women, negative&#xD;
             pregnancy test results should be confirmed before the administration of the&#xD;
             investigational drug and appropriate contraception be used. Pregnant and&#xD;
             breast-feeding women cannot be included)&#xD;
&#xD;
          4. Patients who can consent to participate in this clinical trial&#xD;
&#xD;
          5. Patients who understand this trial and comply with all protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the following clinical symptoms diagnosed using DSM-IV:&#xD;
&#xD;
               -  Delirium, dementia, amnestic or other cognitive disorders&#xD;
&#xD;
               -  Schizophrenia or schizoaffective disorder&#xD;
&#xD;
          2. Patients who do not respond to clozapine&#xD;
&#xD;
          3. Patients who are expected to require the administration of prohibited concomitant&#xD;
             drugs during the clinical trial period&#xD;
&#xD;
          4. Patients diagnosed with substance-related disorder according to DSM-IV within the past&#xD;
             3 months (abuse, intoxication, dependency and/or withdrawal symptoms). The abuse of&#xD;
             benzodiazepines is included with the exception of caffeine or nicotine.&#xD;
&#xD;
          5. Patients known to have allergy or hypersensitivity reaction to Ablify(aripiprazole) or&#xD;
             other quinolinones&#xD;
&#xD;
          6. Patients at high risk of suicide attempt or with the history of murder or mental&#xD;
             status test&#xD;
&#xD;
          7. Patients with the history of neuroleptic malignant syndrome&#xD;
&#xD;
          8. Patients with the past history which may cause serious adverse events that can affect&#xD;
             the safety or efficacy evaluation during the clinical trial period&#xD;
&#xD;
          9. Patients with vital sign or ECG results in the clinically significant abnormal&#xD;
             laboratory test Patients with clinically significantly abnormal laboratory results,&#xD;
             vital sign or ECG results&#xD;
&#xD;
         10. Pregnant women or child-bearing women who do not or cannot use appropriate&#xD;
             contraception&#xD;
&#xD;
         11. Patients given psychotropic medications (except benzodiazepines) one day before&#xD;
             baseline visit&#xD;
&#xD;
         12. Patients treated with Fluoxetine for the last 4 weeks&#xD;
&#xD;
         13. Patients who participated in clinical trials with other investigational drugs for the&#xD;
             last one month&#xD;
&#xD;
         14. Patients with the history of convulsive disorder&#xD;
&#xD;
         15. Patients with the history of more than 4 mood episodes each year (rapid cycling)&#xD;
             during the last 2 years prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won-Myong Bahk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Mary's Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jeong, Yonghui</name_title>
    <organization>Korea Otsuka Pharmaceutical Co.,Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

